AcelRx Pharmaceuticals

AcelRx Pharmaceuticals OCF Margin

Delisted

The Operating Cash Flow Margin of AcelRx Pharmaceuticals (ACRX) as of Oct 24, 2026 is -2,686.94 %. In the previous year, Operating Cash Flow Margin was -1,599.72 % — a change of 67.96% (lower).

OCF Margin

-2,686.94 %

YoY

67.96%

Last updated:

Operating Cash Flow Margin of AcelRx Pharmaceuticals is 2023 -2,686.94 % . Operating Cash Flow Margin of AcelRx Pharmaceuticals was 2022 -1,599.72 % . It decreases by 67.96% lower compared to the previous year.

The AcelRx Pharmaceuticals OCF Margin history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

OCF Margin
Date
OCF Margin
Jan 1, 2016
-169.36 USD
Jan 1, 2017
-372.30 USD
Jan 1, 2018
-1,351.70 USD
Jan 1, 2019
-2,235.91 USD
Jan 1, 2020
-710.95 USD
Jan 1, 2021
-1,064.66 USD
Jan 1, 2022
-1,599.72 USD
Jan 1, 2023
-2,686.94 USD
The AcelRx Pharmaceuticals OCF Margin history
YEAROCF MarginYoY
-2,686.94 %+67.96%
-1,599.72 %+50.26%
-1,064.66 %+49.75%
-710.95 %-68.20%
-2,235.91 %+65.42%
-1,351.70 %+263.07%
-372.30 %+119.83%
-169.36 %+63.50%
-103.58 %-84.32%
-660.46 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

AcelRx Pharmaceuticals Stock analysis

What does AcelRx Pharmaceuticals do? AcelRx Pharmaceuticals Inc. is a California-based company specializing in the manufacturing of pain relief medications. The company was founded in 2005 and has since become an innovator in the development of pain medications. AcelRx's business model involves selling its patented products to hospitals and other healthcare facilities, and it is currently expanding into the global market. The company focuses on developing pain medications for emergency medicine and palliative care, with a particular emphasis on delivering medications through sprays or injections for fast-acting relief. AcelRx offers products such as Zalviso, a pain reliever based on Fentanyl nasal sprays used for post-operative pain, and Dsuvia, a sublingual tablet containing the active ingredient Sufentanil for severe pain. The FDA has approved Dsuvia as safe and effective. AcelRx has also entered partnerships with other pharmaceutical companies, such as Grünenthal and Chinese company R-Pharm, to bring its products to the international market. The company is committed to investing in research and development for innovative pain relief solutions, including a new research program targeting the development of medications for neuropathic pain. AcelRx Pharmaceuticals is a positive example of how modern pharmaceuticals can improve healthcare and quality of life. The company has demonstrated its potential through dedication and continuous research and development, and it is likely to make even greater contributions in the future. AcelRx Pharmaceuticals is one of the most popular companies on Eulerpool.

Frequently Asked Questions about AcelRx Pharmaceuticals stock

Operating Cash Flow Margin of AcelRx Pharmaceuticals is -2,686.94 % in 2023.

Operating Cash Flow Margin of AcelRx Pharmaceuticals changed from -1,599.72 % to -2,686.94 %, representing a 67.96% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Operating Cash Flow Margin AcelRx Pharmaceuticals since 2006 – with annual values, charts, and detailed analysis.

OCF margin measures the percentage of revenue converted into operating cash flow. It indicates cash generation efficiency from core business operations.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Operating Cash Flow Margin's AcelRx Pharmaceuticals with sector peers and the industry average to assess whether it is attractive.

To evaluate Operating Cash Flow Margin's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Operating Cash Flow Margin.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Margins — AcelRx Pharmaceuticals

All Key Metrics — AcelRx Pharmaceuticals